November 1 - Sangamo Therapeutics: Not only has Sangamo decided to lay off 162 employees, equivalent to 40% of its U.S. November 1 - Rani Therapeutics: The California-based biotech is sending a quarter of employees out the door to save cash, while also halting work on a neuroendocrine tumor pill named RT-101. November 2 - Seres Therapeutics: After securing the first-ever approval for an oral microbiome therapy in April, Seres is restructuring, sending 41% of staff packing. The workforce reduction, which will impact about 160 people, will take place across the organization. The company plans to report initial phase 2a trial data of its triplet hepatitis B virus therapy, developed in conjunction with Barinthus Bio (formerly Vaccitech) at the upcoming American Association for the Study of Liver Diseases (AASLD) annual meeting. November 7 - Arbutus Biopharma: Arbutus is laying off 24% of its team after recently deciding to redirect money for research programs toward clinical efforts. The immediate clinical focus will be tumor stroma-targeting ADC PYX-201 and secondary program PYX-106 in non-small cell lung cancer. November 8 - Pyxis: Antibody-drug conjugates may be all the rage but Pyxis is cutting 40% of staff to extend its runway. The company is deprioritizing some earlier work a year after GSK axed a partnership worth $1 billion. November 8 - Lyell Immunopharma: In order to extend its cash into 2027, Lyell is laying off a quarter of its employees. Atop the to-do list is its clinical-stage AAV gene therapy programs, while the biotech will look to partner on some of its neurodegenerative assets. November 9 - Regenxbio: A new pipeline prioritization plan has spurred cuts to 15% of employees. Interim CEO Howard Bernstein, M.D., Ph.D., said in a release that the management team and board "firmly believe in the technology and therapeutic potential." Story November 9 - SQZ: SQZ's extended hunt for a strategic alternative has spurred layoffs to 80% of the team. The new cuts include "focused headcount reductions," according to a statement from the company. November 9 - Novavax: Novavax is implementing another round of cost cuts for 2024 in addition to a previously announced savings plan. Gilead confirmed the layoffs to Fierce Biotech in a statement: "While our business is performing well and our clinical momentum continues to accelerate, we are taking measures to further align our business for future growth, including streamlining some areas of the organization to better optimize operational efficiency." The bulk of the layoffs, 41 people, are effective December 15, while a single employee’s layoff was from earlier this year on March 15. The notice date for the workforce reduction was noted as October 4. November 9-Gilead: Gilead Sciences has cut around 45 employees from its Foster City, California office “to further align our business for future growth.” The layoffs were flagged in a California Work Adjustment and Retraining Notification report dated November 3. The spokesperson described the layoffs as “one of the consequences” of Pfizer’s enterprisewide cost realignment program unveiled in October. Currently, around 940 people are employed at the facility. November 14 - Pfizer: The Big Pharma plans to cut about 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K., a company spokesperson told Fierce Pharma. As part of the restructure, Theseus plans to consider a wide range of options, including a potential asset sale, merger or sale of the company. November 14 - Theseus Pharmaceuticals: Four months after a safety signal blew Theseus’ quest to develop a gastrointestinal stromal tumor treatment off course, the company is shrinking its head count by almost three-quarters. November 15 - Atreca: The California-based biotech is reducing its head count by 40% for the second time in three months in a bid to keep the lights on until strategic alternatives can be identified. Either way, staff have been handed pink slips at a number of biotechs, so here they are.Īs always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |